Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Bioanalysis ; 2(8): 1405-14, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21083341

RESUMEN

BACKGROUND: A defined approach to develop and validate an LC-MS/MS assay using dried blood spot (DBS) samples is of great interest to many scientists who are adopting this technology. We have evaluated three distinct sample preparation procedures of DBS samples for LC-MS/MS assay development. RESULTS: A new term 'elution efficiency' is introduced to evaluate the effectiveness of eluting compounds from the DBS cards into the liquid phase. Three different types of DBS cards were studied as part of the sample preparation procedures. A DBS LC-MS/MS method was developed, qualified and then applied to a toxicokinetics study. CONCLUSION: Organic extraction and protein precipitation resulted in significant ion suppression and/or enhancement for FTA(®) Classic or FTA(®) Elute cards. Liquid-liquid extraction produced the least ion suppression/enhancement. Both protein precipitation and liquid-liquid extraction effectively eluted the probe compound from the DBS cards under the conditions tested. However, organic extraction by pure solvents resulted in low elution efficiency.


Asunto(s)
Métodos Analíticos de la Preparación de la Muestra/métodos , Análisis Químico de la Sangre/métodos , Recolección de Muestras de Sangre/métodos , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Animales , Proteínas Sanguíneas/química , Precipitación Química , Desecación , Farmacocinética , Ratas , Terminología como Asunto
2.
Anal Chem ; 82(9): 3834-9, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20387806

RESUMEN

Metabolomics with chromatography-mass spectrometry is often challenging and relies on statistical tools to discern changes in a metabolome. A pooled sample strategy was proposed, consisting of (1) identification of potential marker candidates by detecting changes of metabolites in a few pooled samples between treated and control groups and (2) validation of markers of statistically significant changes with a large set of individual samples. This strategy was enabled by applying a thorough background subtraction approach based on high-resolution mass spectrometry. In a proof-of-principle study, plasma samples were generated and pooled in a 6-week investigational study to identify potential toxicological markers for an observed muscle toxicity associated with the treatment of ibipinabant in dogs. With pooled control samples as backgrounds, potential marker candidates were revealed in the background-subtracted profiles of the pooled ibipinabant-treated samples. After further cleaning with the use of mass defect filtering to exclude drug metabolites and the comparison of profiles between pooled treated samples to eliminate inconsistent peaks, the major biomarker candidates in the profiles were identified to be 19 acylcarnitines. A total of 3 of the 19 acylcarnitines were measured on the set of individual samples to allow for statistical analysis. The results confirmed the significance of acylcarnitine elevations in ibipinabant-treated dogs and indicated that the acylcarnitines could be early markers for the dog-specific toxicity. The advantages of the pooled sample strategy and its potential limitations for metabolomics are discussed.


Asunto(s)
Biomarcadores/análisis , Moduladores de Receptores de Cannabinoides/uso terapéutico , Cromatografía Líquida de Alta Presión , Espectrometría de Masas , Pirazoles/toxicidad , Pirazoles/uso terapéutico , Sulfonamidas/toxicidad , Sulfonamidas/uso terapéutico , Animales , Moduladores de Receptores de Cannabinoides/efectos adversos , Moduladores de Receptores de Cannabinoides/toxicidad , Cromatografía Líquida de Alta Presión/métodos , Enfermedades de los Perros/tratamiento farmacológico , Perros , Humanos , Obesidad/tratamiento farmacológico , Obesidad/veterinaria
3.
Pharmacogenet Genomics ; 18(10): 903-10, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18794727

RESUMEN

OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists can cause peripheral edema in susceptible individuals. To investigate the mechanistic basis underlying this adverse event, we performed a candidate gene analysis of patients enrolled in clinical trials of muraglitazar, an investigational PPARalpha/gamma dual agonist, and developed a cell culture-based gene expression assay and nonhuman primate model of edema to study the edemagenic properties of PPARgamma agonists. METHODS: A total of 213 single nucleotide polymorphisms (SNPs) in 63 genes were genotyped in 730 participants. Chi-square and logistic regression analyses were used to test for association with edema. Transcriptional responses to PPARgamma agonists were evaluated in Calu-6 cells using quantitative real-time PCR. Male Cynomolgus monkeys were treated with PPAR agonists and were evaluated for edema using MRI. RESULTS: SNPs in renin (rs2368564) and endothelin-1 (rs5370) were associated with reduced risk of edema (P=0.003 and P=0.028, respectively) and an SNP in beta1 adrenergic receptor (rs1801253) was associated with increased susceptibility to edema (P=0.034). Gene expression studies revealed that renin and endothelin-1 were regulated by PPARgamma in Calu-6 cells. A survey of 10 PPARgamma agonists further revealed that a compound's in vitro potency was correlated with its edemagenic potential leading to the prediction that one of three previously uncharacterized PPARgamma agonists would cause less edema. This prediction was validated in a nonhuman primate model of PPARgamma agonist-induced edema. CONCLUSION: Our results implicate a key role for renin and endothelin-1 in the edema caused by PPARgamma agonists and demonstrate how knowledge gained from pharmacogenetic studies can be applied in drug discovery.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/genética , Edema/metabolismo , Endotelina-1/biosíntesis , Regulación de la Expresión Génica , PPAR gamma/agonistas , PPAR gamma/metabolismo , Farmacogenética/métodos , Polimorfismo de Nucleótido Simple , Renina/biosíntesis , Animales , Femenino , Glicina/análogos & derivados , Glicina/farmacología , Humanos , Macaca fascicularis , Masculino , Oxazoles/farmacología , Análisis de Regresión
4.
Breast Cancer Res Treat ; 103(3): 331-41, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17061046

RESUMEN

Increased breast cancer risks have been reported among women with gross cystic breast disease (GCBD), although the mechanism for this increase remains unexplained. Relationships between GCBD characteristics, breast cancer risk factors, and the biochemical composition and growth properties of 142 breast cyst fluid (BCF) samples were studied among 93 women with GCBD. Concentrations of melatonin, estrogen (17-beta-estradiol), dehydroepiandrosterone-sulfate (DHEA-S), epidermal growth factor (EGF), transforming growth factor beta (TGF-B1 and TGF-B2), sodium (Na), and potassium (K) were quantified in BCF samples, and human breast cancer cells (MCF-7) were treated with BCF in vitro. Patients were grouped according to BCF Na:K ratios previously linked with increased breast cancer risks (Na:K 3, Type 2) and mixed cyst groups. Women with larger and more frequently occurring cysts had higher BCF estrogen and DHEA-S, and lower TGF-B1 levels. Women with Type 1 cysts had elevated BCF melatonin, estrogen, DHEA-S, and EGF, and lower concentrations of TGF-B2 compared to women with Type 2 cysts. BCF generally inhibited cell growth relative to serum-treated controls, consistent with previous studies. Melatonin and estrogen in BCF independently predicted growth inhibition and stimulation, respectively. Biological monitoring of BCF may help identify women with GCBD at greatest risk for breast cancer development.


Asunto(s)
Quiste Mamario/metabolismo , Neoplasias de la Mama/metabolismo , Líquido Quístico/metabolismo , Estrógenos/biosíntesis , Regulación Neoplásica de la Expresión Génica , Melatonina/biosíntesis , Adulto , Línea Celular Tumoral , Sulfato de Deshidroepiandrosterona/química , Factor de Crecimiento Epidérmico/biosíntesis , Estradiol/biosíntesis , Femenino , Humanos , Persona de Mediana Edad , Factor de Crecimiento Transformador beta/biosíntesis
5.
Toxicol Lett ; 146(3): 197-205, 2004 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-14687757

RESUMEN

An evaluation of high-throughput Fourier-transform infrared spectroscopy (FT-IR) as a technology that could support a "metabonomics" component in toxicological studies of drug candidates is presented. The hypothesis tested in this study was that FT-IR had sufficient resolving power to discriminate between urine collected from control rat populations and rats subjected to treatment with a potent inflammatory agent, bacterial lipopolysaccharide (LPS). It was also hypothesized that co-administration of LPS with ranitidine, a drug associated with reports of idiosyncratic susceptibility, would induce hepatotoxicity in rats and that this could be detected non-invasively by an FT-IR-based metabonomics approach. The co-administration of LPS with "idiosyncratic" drugs represents an attempt to develop a predictive model of idiosyncratic toxicity and FT-IR is used herein to support characterization of this model. FT-IR spectra are high dimensional and the use of genetic programming to identify spectral sub-regions that most contribute to discrimination is demonstrated. FT-IR is rapid, reagentless, highly reproducible and inexpensive. Results from this pilot study indicate it could be extended to routine applications in toxicology and to supporting characterization of a new animal model for idiosyncratic susceptibility.


Asunto(s)
Espectroscopía Infrarroja por Transformada de Fourier/métodos , Pruebas de Toxicidad/métodos , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas , Análisis Discriminante , Susceptibilidad a Enfermedades , Antagonistas de los Receptores H2 de la Histamina/metabolismo , Antagonistas de los Receptores H2 de la Histamina/toxicidad , Lipopolisacáridos/toxicidad , Hepatopatías/orina , Masculino , Modelos Animales , Proyectos Piloto , Ranitidina/toxicidad , Ratas , Ratas Sprague-Dawley , Espectroscopía Infrarroja por Transformada de Fourier/instrumentación , Espectroscopía Infrarroja por Transformada de Fourier/normas
6.
Mol Cell Biochem ; 247(1-2): 205-10, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12841649

RESUMEN

Chlorogenic acid (CGA) is considered to act as an antioxidant. However, the inhibitory effects of CGA on specific radical species are not well understood. Electron spin resonance (ESR) in combination with spin trapping techniques was utilized to detect free radicals. 5,5-Dimethyl-1-pyrroline-N-oxide (DMPO) was used as a spin trapping reagent while the Fenton reaction was used as a source of hydroxyl radical (*OH). We found that CGA scavenges *OH in a dose-dependent manner. The kinetic parameters, IC50 and Vmax, for CGA scavenging of *OH were 110 and 1.27 microM/sec, respectively. The rate constant for the scavenging of *OH by CGA was 7.73 x 10(9) M(-1) sec(-1). Our studies suggest that the antioxidant properties of CGA may involve a direct scavenging effect of CGA on *OH.


Asunto(s)
Ácido Clorogénico/farmacología , Radical Hidroxilo/química , Ácido Clorogénico/química , Óxidos N-Cíclicos/química , Óxidos N-Cíclicos/farmacología , Relación Dosis-Respuesta a Droga , Espectroscopía de Resonancia por Spin del Electrón , Depuradores de Radicales Libres/química , Depuradores de Radicales Libres/farmacología , Concentración 50 Inhibidora , Detección de Spin
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA